Kalaris Therapeutics stockholders elect two Class II directors, ratify Deloitte as auditor

Kalaris Therapeutics, Inc.

Srinivas Akkaraju and Andrew Oxtoby elected as Class II directors for three-year terms expiring 2028.
Akkaraju: 14,626,646 for, 144,695 withheld; Oxtoby: 14,668,424 for, 102,917 withheld.
Ratification of Deloitte & Touche as independent auditor for FY2025 approved with 16,090,928 for, 6,975 against, 1,786 abstain.
Broker non-votes of 1,328,348 on director elections due to routine matters.

item 5.07

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.